Nemeroff C.B.
The corticotropin — releasing factor (CRF) hypothesis of depression:
new findings and new directions // Mol. Psychiat. — 1996; 1: 336.
Nierenberg A.A.
Long-term management of chronic depression // J. Clin
Psychiat. — 2001. — 62 (Suppl 6): 17—21.
NIMN
Consensus Development Conference. Consensus Development Conference
Statement. Mood disorders: pharmacologic prevention of recurrences // Amer.
J. Psychiat. — 1985; 142: 496—476.
Nurnberger JI Jr, Gershon E.S., Simmons S. et al.
Behavioral, biochemical and
neuroendocrine responses to amphetamine in normal twins and «well-state»
bipolar patients // Psychoneuroendocrinol. — 1982; 7(2—3): 163—76.
Pandey G.N., Dwivedi Y., Ren
X.
et al.
// Neurochem. Res. — 2006; 31(2): 167—76.
Paykel E.S.
Contribution of life events to causation of psychiatric illness // Psychol.
Med. — 1978; 8(2): 245—53.
Penninx B., Beekman A., Honig A. et al.
Depression and cardiac mortality // Arch.
Gen. Psychiat. — 2001. — 58: 221—227.
Prien R.F., Kupfer D.J., Mansky P.A. et al.
Drug therapy in the prevention of
recurrences in unipolar and bipolar affective disorders // Arch. Gen.
Psychiat. — 1984; 41(11): 1096—1104.
Regenold W.T., Thapar R.K., Marano C. et al.
Increased prevalence of type 2
diabetes mellitus among psychiatric in patients with bipolar I affective and
schizoaffective disorders independent of psychotropic drug use // J. Affect
Disord. — 2002; Jun; 70(1): 19—26.
Roy A., De Jong J., Linnoila M.
Cerebrospinal fluid monoamine metabolites and
suicidal behavior in depressed patients. A 5-year follow-up study // Arch. Gen.
Psychiat. — 1989; 46(7): 609—12.
427
Rush A.J., Giles D.E., Schlesser M.A. et al
. Dexamethasone response, thyrotropin-
releasing hormone stimulation, rapid eye movement latency and sybtipes of
depression. Biol // Psychiat. — 1997; 41: 915—928.
Rush A.J., Kupfer D.J.
Strategies and tactics in the treatment of depression. In:
Gabbard GO (ed) Treatment of Psychiatric Disorders. Third Edition. — 2001,
American Psychiatric Publishing Inc, Washington, DC, Р. 1417—1439.
Sachs G., Sanchez R., Marcus R. et al.
Aripiprazole Study roup. Aripiprazole in the
treatment of acute manic or mixed episodes in atients with bipolar I disorder:
a 3-week placebo-controlled study // J. Psychopharmacol. — 2006; Jul; 20(4):
536—46.
Schou M.
Suicidal behavior and prophylactic lithium treatment of major mood
disorders: review of reviews / Suicide life Threat Behav. – 2000; 30: 289—293.
Segal Z.V., Kennedy S.H., Cohen N.L. and the CANMAT Depression Work Group.
Clinical guidelines for the treatment of depressive disorders. V. Combining
psychotherapy and pharmacotherapy // Can. J. Psychiat. — 2001; 46(Suppl 1):
595—625.
Shrivastava R.K., Cohn C., Crowder J. et al.
Long-term safety and clinical
acceptability of venlafaxine in outpatients with major depression // J. Clin.
Psychopharmacol. — 1994; 14: 322—329.
Simhandl C., Denk E., Thau K.
The comparative efficacy of carbamazepine low and
high serum level and lithium carbonate in the prophylaxis of affective
disorders // J. Affect Disord. — 1993; 28: 221—231.
Skare S.S., Dysken M.W., Billington C.J
. A review of GHRH stimulation test in
psychiatry / Biol Psychiat. — 1994; 36: 249—265.
Solomon D.A., Keller M.B, Leon A.C. et al
. Recovery from major depression. A 10-
year prospective follow-up across multiple episodes // Arch. Gen. Psychiat. —
1997; 54: 1001—1006.
Souza F.G.M., Goodwin G.M.
Lithium treatment and prophylaxis in unipolar
depression: meta-analysis // Br. J. Psychiat. — 1991; 158: 666—675.
Stein R., Zitner L., Jensen Р.
Interventions for Adolescent Depression in Primary
Care // Pediatrics. — 2006; 118(2): 669—682.
Storosum J.C., Elferink A.J., van Zwieten B.J. et al.
Short-term efficacy of tricyclic
antidepressants revisited:meta-analytic study // Europ. Neuropsychopharma-
col. — 2001; 11: 173—180.
Suppes T., Brown E., Schuh L.M. et al.
Rapid versus non-rapid cycling as a predictor
of response to olanzapine and divalproex sodium for bipolar mania and
maintenance of remission: post hoc analyses of 47-week data // J. Affect
Disord. — 2005; Dec; 89(1—3): 69—77.
Thase M.E.
Relapse and recurrence in unipolar major depression: short-term and
long-term approaches // J. Clin. Psychiat. — 1990; 51 (Suppl 6): 51—57.
Thanfadurai P., Gopalakrishnan R., Kurian S., Jacob K.S.
Diagnostic stability and
status of acute and transient psychotic disorders // British Journal of
Psychiatry. — 2006. — 188(3): 293.
Thase M.E., Greenhouse J.B., Frank E. et al.
Treatment of major depression with
psychotherapy or psychotherapy-pharmacotherapy combination // Arch. Gen.
Psychiat. — 1997; 54: 1009—1015.
Thornicroft G., Sartorius N.
The course and outcome of depression in different
cultures: 10-year follow-up of the WHO Collaborative Study on the Assessment
of Depressive Disorders // Psucholog. Med. — 1993; 23: 1023—1032.
Tohen M., Vieta E., Calabrese J. et al.
Efficacy of olanzapine and olanzapine-
fluoxetine combination in the treatment of bipolar I depression // Arch. Gen.
Psychiat. — 2003; Nov; 60(11): 1079—88.
Tsuang M.T., Faraone S.V.
The Genetics of Mood Disorders. — Baltimore, Johns
Hopkins University Press, 1990.
Ustun T.B., Sartorius N.
(Eds.) Mental Illness in General Health Care: An
International Study. — Chichester :Willey, 1995.
van Praag H.M., Korf J.
A pilot study of some kinetic aspects of the metabolism of
5-hydroxytryptamine in depressive patients / Biol. Psychiat. — 1971; 3(2):
105—12.
Vieta E., Bourin M., Sanchez R. et al.
Aripoprazole Study Group. Effectiveness of
aripiprazole v. haloperidol in acute bipolar mania: double-blind, randomised,
comparative 12-week trial // Brit. J. Psychiat. — 2005; Sep; 187: 235—42.
Weissman M.M., Wickramaratne P., Nomura Y. et al.
Families at high and low risk
for depression: a 3-generation study // Arch. Gen. Psychiat. — 2005; Jan;
62(1): 29—36.
Wirz-Justice A., van den Hoofdakker R.H.
Sleep deprivation in depression: what do
we know, where do we go? // Biol. Psychiat. — 1999; 46: 445—453.
Wittchen H.U.
Epidemiology of affective disorders. In:Helmchen H., Henn F.,
Lauter H., Sartorius N. (eds) Contemporary Psychiatry. — 2000. — Vol. 3.
Springer, Heidelberg. P. 231—241.
Wolkowitz O.M.
Neurotransmitters, neurosteroids and neurotrophins: new models
of the pathophysiology and treatment of depression // W.J.B.P. — 2003; 4(3):
98—103.
World
Health Organization (2001) The World Health Report 2001 — Mental
Health: New Understanding, New Hope. Geneva: World Health Organization.
Yatham L.N., Goldstein J.M., Vieta E. et al.
Atypical antipsychotics in bipolar
depression: potential mechanisms of action // J. Clin. Psychiat. — 2005; 66
(Suppl 5): 40—8.
Zobel A.W., Nickel T., K
ũ
nzel H.E. et al.
Effects of the high-affinity corticotropin-
releasing hormone receptor 1 antagonist R121919 in major depression: the first
20 patients treated // J. Psychiatr. Res. — 2000; 34: 171—181.
429
Достарыңызбен бөлісу: |